News Organogenesis Holdings Inc. Nasdaq

Equities

AHPAU

KYG0726L1095

Delayed Nasdaq Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+1.51%	+0.58%

05-13	Morgan Stanley Lowers Price Target on Organogenesis Holdings to $3 From $3.50, Keeps Equalweight Rating	MT
05-10	Health Care Edges Higher Amid Rotation to Utilities - Health Care Roundup	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Spotlight: Healthcare and Tech VTAK, ORGO, CDIO, LAZR, VLCN	05-14	AQ
Morgan Stanley Lowers Price Target on Organogenesis Holdings to $3 From $3.50, Keeps Equalweight Rating	05-13	MT
Health Care Edges Higher Amid Rotation to Utilities - Health Care Roundup	05-10	DJ
Organogenesis: Q1 Earnings Snapshot	05-09	AQ
Earnings Flash (ORGO) ORGANOGENESIS HOLDINGS Posts Q1 Revenue $110M, vs. Street Est of $101.1M	05-09	MT
Transcript : Organogenesis Holdings Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
Organogenesis Holdings Inc. Reports First Quarter 2024 Financial Results	05-09	AQ
Organogenesis Holdings Inc. Reaffirms Earnings Guidance for the Year Ending December 31, 2024	05-09	CI
Organogenesis Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis	05-02	AQ
Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis	05-02	CI
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024	04-16	AQ
Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case	04-03	AQ
Transcript : Organogenesis Holdings Inc., Q4 2023 Earnings Call, Feb 29, 2024	02-29
Organogenesis: Q4 Earnings Snapshot	02-29	AQ
Organogenesis Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Earnings Flash (ORGO) ORGANOGENESIS HOLDINGS Posts Q4 Revenue $99.7M, vs. Street Est of $109.1M	02-29	MT
Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance	02-29	AQ
Organogenesis Holdings Inc. Provides Earnings Guidance for the First Quarter and for the Year Ending December 31, 2024	02-29	CI
Organogenesis Holdings Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Organogenesis Holdings Inc. Nasdaq

Equities

AHPAU

KYG0726L1095

Summary

Filters